[Usefulness of (18)F-fluorodeoxyglucose-positron emission tomography-computerized tomography in the identification of the primary tumor in patients with cancer of unknown origin]

Med Clin (Barc). 2013 Jan 5;140(1):14-9. doi: 10.1016/j.medcli.2012.04.033. Epub 2012 Nov 21.
[Article in Spanish]

Abstract

Background and objective: We determined the utility of the (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)-computerized tomography (CT) in the localization of the primary tumor in patients with tumor of unknown origin (TUO).

Patients and method: (18)F-FDG PET-CT scans, performed between November 2006 and November 2010, in search for the primary tumor in patients with TUO, were retrospectively evaluated. Patients underwent a standard PET-CT, 50-60minutes after intravenous injection of 296-370MBq (18)F-FDG. PET-CT studies were assessed as pathological, with/without identification of the primary tumour and no pathological. Final diagnosis was established by histological confirmation and/or clinical/radiologic follow-up longer than 6 months.

Results: We studied 74 patients (59 males, 15 females), with ages ranging from 41-89 years. In 38 (51%) patients the PET-CT assessed the correct origin of the primary tumour. In 8 cases, a histological confirmation in the primary lesion was obtained. In 4 patients the PET-CT showed a false positive result.

Conclusion: PET-CT scanning identified 51% of the primary sites in our sample of patients.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biopsy
  • False Positive Reactions
  • Female
  • Fluorine Radioisotopes*
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Multimodal Imaging*
  • Neoplasms, Unknown Primary / diagnostic imaging*
  • Neoplasms, Unknown Primary / pathology
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*
  • Retrospective Studies
  • Tomography, X-Ray Computed*

Substances

  • Fluorine Radioisotopes
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18